Skip to main content
Home

Search form

  • ABOUT US
    • ECFS Society Details
      • Society Information
      • Applications for Support
    • ECFS Membership
      • Membership Subscription
      • Membership Demographics
    • Other Information
      • Latest News
      • Job Opportunities
      • Grants and Programmes
      • Links
  • RESEARCH
    • ECFS Projects
      • ECFS Clinical Trials Network
      • ECFS Patient Registry
    • ECFS Working Groups
      • Cystic Fibrosis Molecular and Cell Biology and Physiology Basic Science
      • Diagnostic Network
      • Exercise
      • Neonatal Screening
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Special Projects
      • ECFS / CF Europe Post-Doctoral Research Fellowship
      • CFQ-R questionnaire and CF candidates for lung transplant
      • EU funded projects
      • MucoFong International Project
      • Complete CFTR gene mutation analysis in European patients with Cystic Fibrosis
    • Past Working Groups
      • ECFS Gene Modifier Working Group
      • ECFS Non Tuberculous Mycobacteria Working Group
  • CARE
    • ECFS Standards Of Care
      • Introduction
    • ECFS Working Groups
      • Cystic Fibrosis Molecular & Cell Biology and Physiology Basic Science
      • Exercise
      • Diagnostic Network
      • Neonatal Screening
      • Mental Health
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Allied Health Professionals
      • AHP Nursing Research
      • ECFS Nursing Special interest Group
      • European CF Pharmacy Group
      • European Cystic Fibrosis Nutrition Group
      • European Psychosocial Special Interest Group
      • International Physiotherapy Group
  • EDUCATION
  • CONFERENCES & EVENTS
    • European Cystic Fibrosis Conference
    • ECFS Basic Science Conference
    • Conference resources
    • Future ECFS events
    • Other events
    • Past ECFS conferences
  • PUBLICATIONS
    • About Publications
      • The Journal of Cystic Fibrosis
      • ECFS Newsletter
      • ECFS Book
      • ERS Monograph
    • Resources
      • Search All Resources
      • CF Research News
      • Consensus Reports
      • ECFS Guidelines
      • Free Access Articles
      • CF Literature
  • MEMBERSHIP
  • LOG IN

Other Guidelines

Treatment of Idiopathic Chronic Pancreatitis (ICP) with ivacaftor in a Cystic Fibrosis (CF) carrier who also had a second inherited risk factor for pancreatitis called Methylmalonic Acidemia

  • Read more about Treatment of Idiopathic Chronic Pancreatitis (ICP) with ivacaftor in a Cystic Fibrosis (CF) carrier who also had a second inherited risk factor for pancreatitis called Methylmalonic Acidemia

Description of children who changed diagnosis from indeterminate newborn screening to cystic fibrosis

  • Read more about Description of children who changed diagnosis from indeterminate newborn screening to cystic fibrosis

Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis (CF): a systematic review

  • Read more about Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis (CF): a systematic review

Prevalence, management and outcome of Italian infants with cystic fibrosis screening positive inconclusive diagnosis

  • Read more about Prevalence, management and outcome of Italian infants with cystic fibrosis screening positive inconclusive diagnosis

Using inhaled aztreonam in the treatment of exacerbations of cystic fibrosis

  • Read more about Using inhaled aztreonam in the treatment of exacerbations of cystic fibrosis

Mycobacterium abscessus smooth and rough colony variants in cystic fibrosis patients

  • Read more about Mycobacterium abscessus smooth and rough colony variants in cystic fibrosis patients

Laboratory reporting on the clinical spectrum of CFTR p.Arg117His: still room for improvement

  • Read more about Laboratory reporting on the clinical spectrum of CFTR p.Arg117His: still room for improvement

Adjusting the dose of triple therapy (Elexacaftor/Tezacaftor/Ivacaftor) to reduce mental health side effects

  • Read more about Adjusting the dose of triple therapy (Elexacaftor/Tezacaftor/Ivacaftor) to reduce mental health side effects

Patients with F508del/5T;TG12 CFTR genotype

  • Read more about Patients with F508del/5T;TG12 CFTR genotype

Inflammation and infection change what mucus is made of, how much gets made, and how much it can dissolve

  • Read more about Inflammation and infection change what mucus is made of, how much gets made, and how much it can dissolve
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next
  • last
Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2022. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)